#

Biotechnology

: 112
A Cathie Wood ETF has invested in Scribe, a clinical-stage developer of gene therapies for heart diseases / Photo: LinkedIn / Catherinedwood
Small Caps·
Cathie Wood's ARK Genomic Revolution ETF buys newly public biotech Scribe
BofA cut its price target for Papa Johns shares to $34, 9% below their current market price / Photo: Linkedin.com
Small Caps·
Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal
Anthropic unveiled Claude Science, an AI platform for scientific research, and also announced the launch of preclinical drug development programs. Photo: Ousa Chea / Unsplash.com
Review·
Anthropic will focus on drug development. How can one profit from AI in the pharmaceutical sector?
Abivax Biotech Soars 36%: New Tests Allay Investors Fears / Photo: Abivax.com
News·
Abivax shares soared 36%. The company dispelled concerns about a cancer-causing drug
Year to date, Hertzs stock price has fallen 50% / Photo: Facebook / Hertz
Small Caps·
Small caps last week: Hertz's dark day, Wendy’s meme rally, OpenAI IPO beneficiaries
It is possible that Elon Musks SpaceX could face a correction in the foreseeable future. Photo: SpaceX / Unsplash.com
Review·
Fantastic mega-adventures, magical healings, and amazing transformations
In April 2020, Legend raised $150 million from institutional investors, followed by a Nasdaq IPO in June of that year / Photo: LinkedIn / Nasdaq
Small Caps·
Small biotech Legend intends to compete with Big Pharma. Wall Street believes in it.
The all-stock merger, along with other upbeat announcements, lifted the stock / Photo: Unsplash / Mathurin NAPOLY / matnapo
Small Caps·
Biotech Boundless skyrockets 90% on merger with Serapha, bucking broad selloff
A potential IPO of Anthropic could be a big boost for firms with exposure to the maker of Claude / Photo: Yalcin Sonat / Shutterstock.com
Small Caps·
Small caps last week: Anthropic IPO beneficiaries, GLP-1 craze winners, biotech rally
Kardigans IPO took place amid a recovery in the biotech market / Photo: Kardigan
News·
Kardigan IPO: Shares in the developer of AI-powered cardiac drugs are now available
Immix initially focused on developing oncology and anti-inflammatory therapies / Photo: Shutterstock.com
Small Caps·
Immix Biopharma is targeting an $11 bln market. How much upside does the stock offer?
Wizz Air withheld 2027 guidance due to uncertainty around the Iran conflict / Photo: Toni. M / Shutterstock.com
Small Caps·
Small caps last week: Record biotech IPO, Wizz Air's solid top line, SpaceX effect
Load more